Roth Capital Reaffirms Buy Rating for Fortress Biotech (NASDAQ:FBIO)

Roth Capital reiterated their buy rating on shares of Fortress Biotech (NASDAQ:FBIO – Get Rating) in a research note released on Tuesday, PriceTargets.com reports. Other research analysts also recently issued research reports about the stock. StockNews.com raised shares of Fortress Biotech from a sell rating to a hold rating in a research note on Saturday, […]

Related Keywords

,Advisor Group Holdings Inc ,Cantor Fitzgerald ,Arete Wealth Advisors ,Envestnet Asset Management Inc ,Nasdaq ,Fortress Biotech Company Profile ,Fortress Biotech Inc ,Wells Fargo Company ,Biotechnology Product Development ,Roth Capital ,Fortress Biotech ,Get Rating ,Moderate Buy ,Wealth Advisors ,Group Holdings ,Envestnet Asset Management ,Dermatology Product Sales ,Fortress Biotech Daily ,Nasdaq Fbio ,Fbio ,Medical ,21976u10 ,Reiterated Rating ,